Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.72 |
| ▸ | BCR | P11274 | 10/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.68 |
| ▸ | PRKCA | P17252 | 4/20 | 0.67 |
| ▸ | EGFR | P00533 | 4/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | BTK | Q06187 | 1/20 | 0.63 |
| ▸ | ITK | Q08881 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17263678 | 0.92 | ABL1 (0.66) | ABL1BCRSRCPDGFRAPDGFRB | |
| SCHEMBL1908559 | 0.91 | ABL1 (0.65) | ABL1BCRSRCPDGFRAPDGFRB | |
| SCHEMBL2984112 | 0.90 | CAMKK2 (0.70) | ABL1BCRSRCPDGFRAPDGFRB | |
| SCHEMBL28891228 | 0.90 | ABL1 (0.64) | ABL1BCRSRCPDGFRAPDGFRB | |
| SCHEMBL29707254 | 0.89 | ABL1 (0.71) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL533540 | 0.89 | ABL1 (0.71) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL12715062 | 0.89 | ABL1 (0.77) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL1653881 | 0.88 | ABL1 (0.72) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL13531218 | 0.88 | ABL1 (0.69) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL1566674 | 0.88 | ABL1 (0.69) | ABL1BCRPDGFRAPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | claimed |
| CN-122036689-A | Nilotinib preparation method of nylon | 苏州特瑞药业股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250057841-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | HANDA ONCOLOGY, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250049797-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | HANDA ONCOLOGY, LLC (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240366603-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | HANDA ONCOLOGY, LLC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12064430-B2 | Kinase inhibitor salts and compositions thereof | HANDA ONCOLOGY, LLC (US) | 2024-08-20 | — | — | US | disclosed |
| US-12064428-B2 | Kinase inhibitor salts and compositions thereof | HANDA ONCOLOGY, LLC (US) | 2024-08-20 | — | — | US | disclosed |
| US-12065426-B2 | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same | LAURUS LABS LIMITED (IN) | 2024-08-20 | — | — | US | disclosed |
| EP-4045494-B1 | SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE | ESCO ASTER PTE LTD (SG) | 2023-10-11 | — | — | EP | disclosed |
| EP-4045494-B1 | SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE | ESCO ASTER PTE LTD (SG) | 2023-10-11 | — | — | EP | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008137770-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137605-A1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2008-11-13 | — | — | WO | disclosed |
| US-20080269269-A1 | Protein kinase inhibitor; purity; polymorphism | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080269269-A1 | Protein kinase inhibitor; purity; polymorphism | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080188656-A1 | Process for the Synthesis of 5- (Methyl-1H-Imidazol-1-Yl) -3- (Trifluoromethyl) -Benzeneamine | NOVARTIS AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188656-A1 | Process for the Synthesis of 5- (Methyl-1H-Imidazol-1-Yl) -3- (Trifluoromethyl) -Benzeneamine | NOVARTIS AG (CH) | 2008-08-07 | — | — | US | disclosed |
| WO-2008058037-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007015870-A2 | CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE | NOVARTIS AG (CH) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269269-A1 | Protein kinase inhibitor; purity; polymorphism | MAP4K2, MAP4K1, CSNK1A1 | ABL1 75/4885BCR 1101/4885SRC 372/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | ABL1 240/4885BCR 2482/4885SRC 2138/4885 |
| US-12064428-B2 | Kinase inhibitor salts and compositions thereof | SRC, STK25, STK35 | ABL1 9/4885BCR 630/4885SRC 1/4885 |
| US-20250049797-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | BRAF, MAP3K15, RAF1 | ABL1 448/4885BCR 3530/4885SRC 45/4885 |
| US-20080188656-A1 | Process for the Synthesis of 5- (Methyl-1H-Imidazol-1-Yl) -3- (Trifluoromethyl) -Benzeneamine | CYP1B1, CYP1A1, PRMT5 | ABL1 10/4885BCR 502/4885SRC 731/4885 |
| US-12064430-B2 | Kinase inhibitor salts and compositions thereof | BRAF, MAP3K21, MAP3K20 | ABL1 30/4885BCR 875/4885SRC 12/4885 |
| US-20250057841-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | BRAF, MAP3K15, RAF1 | ABL1 448/4885BCR 3530/4885SRC 45/4885 |
| US-20240366603-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | SRC, ABL1, MCL1 | ABL1 2/4885BCR 196/4885SRC 1/4885 |
| US-12065426-B2 | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same | ABL1, LCK, FYN | ABL1 1/4885BCR 13/4885SRC 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.